New independent analyses presented by Amgen show that Repatha (evolocumab) is highly cost-effective for high-risk patients without prior heart attack or stroke, reducing major cardiovascular events by up to 29%. The VESALIUS-CV trial data demonstrated significant LDL cholesterol lowering and cardiovascular benefits, especially in patients with chronic kidney disease. Long-term follow-up from the FOURIER trial also confirmed sustained cardiovascular risk reduction over more than eight years. These findings support broader use of Repatha to prevent first-time cardiovascular events and improve patient outcomes.
Amgen (AMGN) shares rose 1.03% to USD 465.18 as of Nov 10, 2026 04:11 WIB on Pluang. The stock trades near its 52-week high of USD 478.48, reflecting steady investor interest. Despite 72% of Pluang orders being sell, the company maintains a 2.19% dividend yield and a market cap of $249.05B.
